Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 19/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012982 | 0.91 | PTGDR (0.84) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL2001955 | 0.83 | CYP3A4 (1.00) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL2006593 | 0.80 | CYP3A4 (0.77) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL2010155 | 0.79 | CYP3A4 (0.77) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL2003621 | 0.79 | CYP3A4 (0.82) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL2009085 | 0.79 | PTGDR (1.00) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL1998637 | 0.78 | PTGDR (1.00) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL12570826 | 0.78 | CYP3A4 (0.80) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL2004019 | 0.78 | PTGDR (1.00) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 | |
| SCHEMBL12570965 | 0.77 | CYP3A4 (0.87) | PTGDRPTGDR2CYP3A4ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2164828-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | Amgen Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | CCL11, LTC4S, TSLP | PTGDR 296/4885PTGDR2 253/4885CYP3A4 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.